REG-4basebio Plc: Exercise of Options

4BasebioAnnouncement

17/02/2024 21:18

6 February 2024

4basebio plc

(“4babsebio” or the "Company")
 

Exercise of Options

Cambridge, UK, 6 February 2024 - 4basebio PLC (AIM: 4BB), an innovation driven
biotechnology company enabling and accelerating development of advanced
therapy medicinal products (ATMPs) through its high performant synthetic DNA
products and non-viral, thermostable nucleic acid delivery platform, announces
that, on 2 February 2024, it received notification from an employee to
exercise EMI options over 9,000 ordinary shares (“New Ordinary Shares”) in
the Company at an exercise price of £3.65 pence per share for total proceeds
of £32,850.

Admission to AIM

Application will be made for the New Ordinary Shares to be admitted to trading
on AIM ("Admission"). It is expected that Admission will become effective at
8.00 a.m. on or around 9 February 2024. The New Ordinary Shares will be issued
credited as fully paid and will rank in full for all dividends and other
distributions declared, made or paid after Admission and will otherwise rank
on Admission pari passu in all respects with the existing ordinary shares.

Total Voting Rights

Following Admission, the total number of ordinary shares in issue will be
12,805,208. The Company does not hold any ordinary shares in treasury.
Therefore, the total number of ordinary shares with voting rights will be
12,805,208. This figure may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
share capital of the Company under the Financial Conduct Authority's
Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 as amended by regulation 11 of the market abuse
(amendment) (EU Exit) regulations 2019/310.

For further enquiries, please contact:

 4basebio PLC                                      +44 (0)12 2396 7943  
 Heikki Lanckriet, CEO                                                  
                                                                        
 Cairn Financial Advisers LLP (Nominated Adviser)  +44 (0)20 7213 0880  
 Jo Turner / Sandy Jamieson                                             
                                                                        
 Cavendish Capital Markets Limited (Broker)        +44 (0)20 7220 0500  
 Geoff Nash/Charlie Beeson                                              



Copyright (c) 2024 PR Newswire Association,LLC. All Rights Reserved